Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2019 | MANTLE-FIRST results: outcomes in R/R younger MCL by therapy type

Umberto Vitolo • 20 Jun 2019
ICML 2019
B-Cell Lymphoma Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Bendamustine Ibrutinib Rituximab
MANTLE-FIRST

The results from the MANTLE-FIRST study are discussed here by Umberto Vitolo, MD, Città della Salute e della Scienza University Hospital, Turin, Italy, at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland. The outcomes of younger patients with relapsed/refractory mantle cell lymphoma (MCL) are explored.

More from Umberto Vitolo

1:56
Copanlisib, rituximab, & bendamustine in transplant-ineligible R/R DLBCL
Umberto Vitolo • 10 Dec 2023
2:13
Rituximab ± lenalidomide as maintenance therapy in elderly patients with R/R FL
Umberto Vitolo • 10 Dec 2023
3:20
Bispecific antibodies in NHL: current insights and ongoing studies
Umberto Vitolo • 15 Jun 2023
1:31
The current state of treatment for limited-stage DLBCL
Umberto Vitolo • 15 Jun 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals